Home
overview
It has been estimated that the drug delivery industry is forecast to grow to 70 billion dollars by the year 2005. Developing various methods of controlled release is important to maintain a drugs’ lifecycle and is a essential tool for patenting new and existing drugs.

SMI's third annual Controlled Release conference will include presentations on:
  • The most recent technological advances in Controlled Release
  • Case study on a successful company's strategies
  • The various methods of delivery and the latest research that is being done in these areas
  • An update on new and existing technologies


Confirmed Speakers so far include:

Dr Alice Loper, Vice President, Schering-Plough
Prof Gert Ragnarsson, Director, Preformulation & Biopharmaceutics, AstraZenecea
Dr Ali Rajabi Siahboomi, Global Technical Director, Modified Release Technologies,
Colorcon
Dr David Cipolla, Director, Pharmaceutical Development, Aradigm
Dr Pierandrea Esposito, Director, Drug Delivery, Serono
Dr Dominic Griffiths, Business Development Manager, Europe, Phoqus
Dr Joerg Breitenbach, Head of Soliqs, Abbott Drug Delivery
Dr Bill Bosch, Director, Dispersion Technology, Elan

Conference programme

8:30 Registration & Coffee

9:00 Chairman's Opening Remarks

Prof Gert Ragnarsson

Prof Gert Ragnarsson, Director, Preformulation & Biopharmaceutics, AstraZeneca

9:10 OVERVIEW OF CONTROLLED RELEASE

Dr Paul Gellert

Dr Paul Gellert, Principal Scientist, AstraZeneca

  • The value of controlled release drug delivery
  • The differing approaches to altering release profiles
  • Successful controlled release product design
  • Controlled release technology gaps
  • The special case of insoluble compounds
  • 9:40 ATTAINING THE DESIRED RELEASE PROFILE

    Dr Alice Loper

    Dr Alice Loper, Vice President, Schering-Plough

  • Optimal drug attributes
  • Attaining the desired release profile
  • Barriers in controlled release drug development
  • How these obstacles are being overcome
  • 10:20 TWO CONCEPTS, ONE TECHNOLOGY

    11:00 Morning Coffee

    11:20 CONTROLLED RELEASE TECHNOLOGIES FOR PROTEINS AND POLYPEPTIDES

    Dr Sabine Meyenburg

    Dr Sabine Meyenburg, Project Leader, Life Cycle Management & Drug Delivery Technologies, Novartis

  • Specifics of controlled release approaches for peptides and proteins
  • Selecting the right technology: a case study
  • Technical hurdles for prototyping and scaling up
  • 12:00 A GENERIC TARGETING AND DEPOSITION TECHNOLOGY USING FUSION PROTEINS

    Dr Neil Parry

    Dr Neil Parry, Science Base Leader, Biosciences, Unilever

  • Development of a fusion protein for targeting and delivery of actives to surfaces
  • Application of technology to Unilever’s business portfolio
  • Opportunities of technology in parallel industries
  • Next steps for the technology platform
  • 12:40 Networking Lunch

    14:00 SUSTAINED RELEASE PREPARATIONS OF PROTEINS AND POLYPEPTIDES

    Dr Tomas Landh

    Dr Tomas Landh, Research Scientist, Novo Nordisk

  • Current trends in SR protein formulations
  • Novo Nordisk protein portfolio and unmet clinical need for SR formulations
  • Towards the needs: balancing in house efforts and external collaborations
  • 14:40 DEVELOPING TECHNOLGIES FOR PROTEIN AND PEPTIDE DELIVERY

    Dr Pierandrea Esposito

    Dr Pierandrea Esposito, Director, Drug Delivery, Serono

  • Strategies to develop delivery systems for proteins and peptides
  • Established vs new delivery technologies
  • Advanced formulation vs chemical modifications
  • New materials for drug delivery
  • Obstacles and benefits in developing new technologies
  • 15:20 Afternoon Tea

    15:40 NOVEL POLYMERS FOR CONTROLLED RELEASE PARENTERAL PROTEIN DELIVERY

    Dr Leo deLeede

    Dr Leo deLeede, Managing Director, OctoPlus Technologies

  • Alternative polymers for polylactic-glycolic acid
  • Controlled release and pulsatile release
  • Polymers for solvent evaporation technologies
  • Polymers for microcapsule formation in a full aqueous environment
  • In vitro and in vivo correlation
  • 16:20 BIOGRADABLE IMPLANTS FOR THE SUSTAINED RELEASE OF SMALL MOLECULES, PEPTIDES AND PROTEINS

    Dr Eric Dadey

    Dr Eric Dadey, Vice President, Drug Delivery, Atrix Laboratories

  • Current implant technologies
  • Formulation and manufacturing overview
  • Factors affecting release kinetics
  • Product profiles: SR of small molecules, peptides and proteins
  • 17:00 Chairman’s Closing Remarks and Close of Day One

    8:30 Re-registration & Coffee

    9:00 Chairman's Opening Remarks

    Dr Ali Rajabi-Siahboomi

    Dr Ali Rajabi-Siahboomi, Global Technical Director, Modified Release Technologies, Colorcon

    9:10 OVERVIEW OF ORAL CONTROLLED RELEASE

    Dr Ross MacRae

    Dr Ross MacRae, Manager, Pharmaceutical Research & Development, Pfizer

  • Utility of oral controlled release
  • Key factors in determining success in delivering oral controlled release profiles
  • Review of major delivery mechanisms
  • Matching candidates with technology
  • 9:40 ORAL MODIFIED RELEASE SYSTEMS

    Dr Ali Rajabi-Siahboomi

    Dr Ali Rajabi-Siahboomi, Global Technical Director, Modified Release Technologies, Colorcon

  • The importance of oral drug delivery
  • Design of formulations suitable for oral drug delivery
  • The technical challenges of oral delivery and how these are being overcome
  • The latest research on technologies for oral slow drug delivery
  • 10:20 THE IMPORTANCE OF CHARACTERISATION IN DRUG DELIVERY DEVELOPMENT

    Dr Claire Madden

    Dr Claire Madden, Project Specialist, Molecular Profiles

  • Why characterise controlled release and pulmonary delivery systems
  • Advances in characterisation technology
  • Applications from formulation development to patent protection
  • 11:00 Morning Coffee

    11:20 CASE STUDY: ADVANCEMENTS IN ORAL DELIVERY

    Dr William Bosch

    Dr William Bosch, Director, NanoSystems, Elan Drug Delivery

  • Formulation and manufacturing overview
  • Pharmacokinetic benefits to poorly water soluble drugs
  • Product enhancement opportunities
  • Recent technology advancement
  • 12:00 A NOVEL APPROACH TO ORAL CONTROLLED RELEASE

    Dr Dominic Griffiths

    Dr Dominic Griffiths, Business Development Manager, Europe, Phoqus

  • Limitations of traditional oral drug delivery and drivers of new technologies
  • Dry powder deposition – a new concept for oral controlled release drug delivery
  • Application of dry powder deposition technology to controlled release oral drug delivery
  • 12:40 Networking Lunch

    14:00 ORAL DELIVERY OF PROTEIN DRUGS

    Dr Steven Dinh

    Dr Steven Dinh, Vice President, Research & Technology, Emisphere Technologies

  • Challenges for oral delivery of macromolecules
  • What needs to be achieved to enable oral delivery of protein drugs?
  • Advances in oral delivery technologies
  • Product case studies: from basic science to clinical development
  • 14:40 DEVELOPMENT CASE STUDY

    Dr Paul Wotton

    Dr Paul Wotton, Global Head, Business Development, SkyePharma

  • How Skye bring products to the market
  • Identifying, establishing and maintaining partnerships
  • Strategies for success
  • 15:20 Afternoon Tea

    15:40 INJECTABLES

    Dr S Moein Moghimi

    Dr S Moein Moghimi, Senior Lecturer, Biopharmacy & Molecular Targeting & Head, Molecular Targeting & Polymer Toxicology Group, University of Brighton

  • Intravenous and subcutaneous routes of entry
  • Applications in controlled delivery of drugs, gene-medicines and diagnostic agents
  • Leading technologies
  • Adverse reactions and future clinical needs
  • 16:20 PULMONARY DRUG DELIVERY

    David Cipolla

    David Cipolla, Director, Pharmaceutical Development, Aradigm

  • Review of existing marketed drug delivery systems
  • Opportunities to improve the existing paradigms
  • Contribution of the drug, formulation, device and patient to achieving efficacious pulmonary delivery
  • Systemic delivery of proteins through the lung
  • Controlled release of drugs via pulmonary delivery
  • 17:00 Chairman's Closing Remarks and Close of Conference

    +

    Workshops

    Negotiating the Collaboration Contract – Tactics and Traps
    Workshop

    Negotiating the Collaboration Contract – Tactics and Traps

    The Hatton, at etc. venues
    11th February 2004
    London, United Kingdom

    The Hatton, at etc. venues

    51/53 Hatton Garden
    London EC1N 8HN
    United Kingdom

    The Hatton, at etc. venues

    HOTEL BOOKING FORM

    Title

    SubTitle
    speaker image

    Content


    Title


    Description

    Download


    WHAT IS CPD?

    CPD stands for Continuing Professional Development’. It is essentially a philosophy, which maintains that in order to be effective, learning should be organised and structured. The most common definition is:

    ‘A commitment to structured skills and knowledge enhancement for Personal or Professional competence’

    CPD is a common requirement of individual membership with professional bodies and Institutes. Increasingly, employers also expect their staff to undertake regular CPD activities.

    Undertaken over a period of time, CPD ensures that educational qualifications do not become obsolete, and allows for best practice and professional standards to be upheld.

    CPD can be undertaken through a variety of learning activities including instructor led training courses, seminars and conferences, e:learning modules or structured reading.

    CPD AND PROFESSIONAL INSTITUTES

    There are approximately 470 institutes in the UK across all industry sectors, with a collective membership of circa 4 million professionals, and they all expect their members to undertake CPD.

    For some institutes undertaking CPD is mandatory e.g. accountancy and law, and linked to a licence to practice, for others it’s obligatory. By ensuring that their members undertake CPD, the professional bodies seek to ensure that professional standards, legislative awareness and ethical practices are maintained.

    CPD Schemes often run over the period of a year and the institutes generally provide online tools for their members to record and reflect on their CPD activities.

    TYPICAL CPD SCHEMES AND RECORDING OF CPD (CPD points and hours)

    Professional bodies and Institutes CPD schemes are either structured as ‘Input’ or ‘Output’ based.

    ‘Input’ based schemes list a precise number of CPD hours that individuals must achieve within a given time period. These schemes can also use different ‘currencies’ such as points, merits, units or credits, where an individual must accumulate the number required. These currencies are usually based on time i.e. 1 CPD point = 1 hour of learning.

    ‘Output’ based schemes are learner centred. They require individuals to set learning goals that align to professional competencies, or personal development objectives. These schemes also list different ways to achieve the learning goals e.g. training courses, seminars or e:learning, which enables an individual to complete their CPD through their preferred mode of learning.

    The majority of Input and Output based schemes actively encourage individuals to seek appropriate CPD activities independently.

    As a formal provider of CPD certified activities, SMI Group can provide an indication of the learning benefit gained and the typical completion. However, it is ultimately the responsibility of the delegate to evaluate their learning, and record it correctly in line with their professional body’s or employers requirements.

    GLOBAL CPD

    Increasingly, international and emerging markets are ‘professionalising’ their workforces and looking to the UK to benchmark educational standards. The undertaking of CPD is now increasingly expected of any individual employed within today’s global marketplace.

    CPD Certificates

    We can provide a certificate for all our accredited events. To request a CPD certificate for a conference , workshop, master classes you have attended please email events@smi-online.co.uk

    Event Title

    Headline

    Text
    Read More

    I would like to speak at an event

    I would like to attend an event

    I would like to sponsor/exhibit at an event

    SIGN UP OR LOGIN

    Sign up
    Forgotten Password?

    Contact SMi GROUP LTD

    UK Office
    Opening Hours: 9.00 - 17.30 (local time)
    SMi Group Ltd, 1 Westminster Bridge Road, London, SE1 7XW, United Kingdom
    Tel: +44 (0) 20 7827 6000 Fax: +44 (0) 20 7827 6001
    Website: http://www.smi-online.co.uk Email: events@smi-online.co.uk
    Registered in England No: 3779287 VAT No: GB 976 2951 71




    Forgotten Password

    Please enter the email address you registered with. We will email you a new password.